老年HIV感染者接受标准抗癌治疗后癌症结局仍较差
调整已实施的首程抗癌治疗后,HIV感染者的全因死亡率在结直肠癌、前列腺癌和乳腺癌中仍显著升高,前列腺癌和乳腺癌的癌症特异性死亡率及复发或死亡风险也更高。
要点
- 老年HIV感染者结直肠癌、前列腺癌和乳腺癌的全因死亡风险显著高于未感染者。
- 前列腺癌和乳腺癌的癌症特异性死亡风险在HIV感染者中呈升高趋势。
- 调整首程抗癌治疗后差异仍存在,提示需关注HIV感染者的癌症结局。
核心结论
- 美国老年HIV感染癌症患者(尤其前列腺癌和乳腺癌)结局差于未感染者,调整首程抗癌治疗后差异仍持续。
临床怎么用
- 对老年HIV感染的前列腺癌和乳腺癌患者,即使接受标准治疗,仍需加强随访和结局监测。
局限性
- HIV感染样本量较小(288例),部分癌症特异性死亡风险置信区间宽且未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: HIV-infected patients with cancer have an elevated cancer-specific mortality rate compared with HIV-uninfected patients with cancer. However, to our knowledge, studies describing this association have not adjusted in detail for cancer treatment, despite evidence of suboptimal cancer treatment in the setting of HIV. OBJECTIVE: To compare cancer-specific mortality in HIV-infected and HIV-uninfected patients with cancer after adjusting for available data on receipt of specific cancer treatments. DESIGN, SETTING, AND PARTICIPANTS: We used Surveillance, Epidemiology, and End Results-Medicare linked data to identify 308 268 patients in the United States (age, ≥65 years), including 288 with HIV infection, with nonadvanced cancers of the colorectum, lung, prostate, or breast diagnosed between 1996 and 2012 who received standard, stage-appropriate cancer treatment during the year after cancer diagnosis. Data analysis was done from August 2016 to September 2018. EXPOSURES: HIV infection identified by the presence of Medicare claims. MAIN OUTCOMES: Overall mortality, cancer-specific mortality, and relapse or cancer-specific mortality after initial treatment. RESULTS: In this database study of 308 268 patients with nonadvanced cancer (168 998 men and 139 270 women; age, ≥65 years), HIV-infected patients (n = 288) had significant elevations in the overall mortality rate compared with HIV-uninfected patients for cancers of the colorectum (hazard ratio [HR], 1.73; 95% CI, 1.11-2.68; P = .02), prostate (HR, 1.58; 95% CI, 1.23-2.03; P < .01), and breast (HR, 1.50; 95% CI, 1.01-2.24; P = .05). Cancer-specific mortality was elevated for prostate (HR, 1.65; 95% CI, 0.98-2.79; P = .06) and breast cancer (HR, 1.85; 95% CI, 0.96-3.55; P = .07). Compared with their HIV-uninfected counterparts, HIV-infected men with prostate cancer also experienced significantly higher rates of relapse or death (HR, 1.32; 95% CI, 1.03-1.71; P = .03) as did HIV-infected women with breast cancer (HR, 1.63; 95% CI, 1.09-2.43; P = .02). CONCLUSIONS AND RELEVANCE: In the United States, elderly HIV-infected patients with cancer, particularly prostate and breast cancers, have worse outcomes than HIV-uninfected patients with cancer. This disparity persists even after adjustment for administered first-course cancer treatments and will become increasingly relevant as the HIV population in the United States continues to age.
引用
- Coghill AE, Suneja G, Rositch AF, et al. HIV Infection, Cancer Treatment Regimens, and Cancer Outcomes Among Elderly Adults in the United States. JAMA Oncol. 2019. PMID: 31369037. doi:10.1001/jamaoncol.2019.1742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。